Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.
PharmaPendium supports drug safety and efficacy decisions for better drug outcomes
You need high-quality data to discover, innovate and develop with confidence. PharmaPendium combines unparalleled regulatory and drug data with full-text search and predictive tools. Reduce animal testing and launch drugs faster with PharmaPendium.
Used by the FDA and the world’s top pharma companies
Get critical insights to predict the success or failure of drug candidates as early as possible
To advance the best drug candidates, you want to prove better performance. PharmaPendium has user-friendly tools to help you analyze safety, deliverability and efficacy data.
Make informed decisions to increase the success of regulatory submissions
Minimize regulatory cycling and avoid failing approval with PharmaPendium.
Discover complete regulatory packages from the EMA and FDA, and FDA Advisory Committee Meeting Documents
Explore previous regulatory submissions and learn from precedents to predict agencies’ requirements
Benchmark against approved and withdrawn drugs with the same mechanism of action as your drug candidates
Rapidly respond to regulatory questions using comparative data from FDA/EMA drug approval and review documents
Analyze the toxicity of drug candidates and advance the 3Rs with the new Tox Navigator
Developed in collaboration with Pfizer, Tox Navigator includes toxicity data from regulatory documents and scientific articles.
Supporting the 3Rs and patient safety assessment, the Tox Navigator helps you:
Convert animal doses to human equivalent doses
Leverage existing data to reduce number of animal studies and design more efficient studies
Investigate adverse drug reactions across different species
Integrate in silico models and other non-animal testing methods
Optimize research efforts by focusing on candidates with favorable safety profiles
Connected, configurable solutions to innovate in R&D
Advance your research with Elsevier’s PharmaPendium and a portfolio of solutions for pharmaceutical R&D.
Innovate with confidence, supported by:
Trusted quality information from regulatory data to peer-reviewed scientific literature
Innovative technology that powers data transformation and analytical and predictive tools
Domain and data science expertise to solve complex problems with data solutions for R&D
Information integrity is essential to your progress. Discover trusted data and tools that deliver critical insights.
Let's shape progress together.
Find precise data to advance your drug portfolio
FDA and EMA documents
Harness the power of PharmaPendium with complete FDA and EMA approval packages and critical FDA Advisory Committee Meeting documents, like in no other tool.
Enhanced visualization
Seamlessly move from table view to interactive charts, graphs and visual aids to easily interrogate and interpret data.
Predictive tools
Predict harmful DDIs using the DDI Risk Calculator and the risk of off-target adverse events using the Safety Margin Tool.
Unparalleled search capabilities
Find information by adverse events (MedDRA), targets, indications, drugs and endpoints using normalized data. Result pages bridge the preclinical to clinical divide.
Real-world evidence from FAERS
Search over 19 million reports in FAERS (FDA Adverse Event Reporting System) to find any adverse event from real-world evidence and post-market drug safety.
High-quality datasets
PharmaPendium’s high-quality datasets are available for off-platform usage. Embed the data into your workflows and models for more accurate search and prediction.
"... PharmaPendium excels in retrieving specific toxicity observations across approval documents categorized by drug and species."
GB
Guy Bouvier, PhD, ERT
Director, Toxicology & Product Safety at Groupe Pierre Fabre
Continuous development and improvement of PharmaPendium has been achieved in collaboration with the FDA for 17 years, as well as with leading pharma partners like Novartis, Sanofi, Merck, Servier and Boehringer Ingelheim.
PharmaPendium is used by:
Toxicologists and safety pharmacologists
DMPK specialists
Clinical researchers
Regulatory affairs experts
Global patient safety experts
Data scientists
PharmaPendium provides you with unique content, all in one place. PharmaPendium data sources include:
Full FDA approval packages
Full EMA approval documents
FDA Advisory Committee Documents
FDA Adverse Event Reporting System (FAERS)
FDA classic collection (covering 1938-1991)
DESI (Drug Efficacy Study Implementation) documents
PharmaPendium includes safety, PK, MET, efficacy, activity, FAERS and drug data, as well as approval packages and documents from the FDA and EMA.
PharmaPendium and Embase combined empower you to find additional indications for drug repurposing of unapproved or approved drugs. With the breadth of data in Embase and PharmaPendium, you can find relevant clinical studies and data to predict the requirements of clinical trial design and to mitigate risk.
In addition to data on approved drugs in PharmaPendium, Embase provides information on unapproved drugs. Embase covers more than 8,500 scientific journals and millions of abstracts from 11,500 conferences worldwide.
The most powerful way to advance your drug portfolio | PharmaPendium. Find it. Predict it.
